Aberrant MYCN Expression Drives Oncogenic Hijacking of EZH2 As a Transcriptional Activator In peripheral T-cell Lymphoma

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2022 Aug 12

PMID 35960849

Authors

Marlies Vanden Bempt

Koen Debackere

Sofie Demeyer

Quentin Van Thillo

Nienke Meeuws

Cristina Prieto

Sarah Provost

Nicole Mentens

Kris Jacobs

Olga Gielen

David Nittner

Seishi Ogawa

Keisuke Kataoka

Carlos Graux

Thomas Tousseyn

Jan Cools

Daan Dierickx

Affiliations

Soon will be listed here.

Abstract

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of hematological cancers arising from the malignant transformation of mature T cells. In a cohort of 28 PTCL cases, we identified recurrent overexpression of MYCN, a member of the MYC family of oncogenic transcription factors. Approximately half of all PTCL cases was characterized by a MYC expression signature. Inducible expression of MYCN in lymphoid cells in a mouse model caused T-cell lymphoma that recapitulated human PTCL with an MYC expression signature. Integration of mouse and human expression data identified EZH2 as a key downstream target of MYCN. Remarkably, EZH2 was found to be an essential cofactor for the transcriptional activation of the MYCN-driven gene expression program, which was independent of methyltransferase activity but dependent on phosphorylation by CDK1. MYCN-driven T-cell lymphoma was sensitive to EZH2 degradation or CDK1 inhibition, which displayed synergy with US Food and Drug Administration-approved histone deacetylase (HDAC) inhibitors.

Citing Articles

Exploring oncogenic roles and clinical significance of EZH2: focus on non-canonical activities.

Wozniak M, Czyz M Ther Adv Med Oncol. 2025; 17():17588359241306026.

PMID: 39776536 PMC: 11705335. DOI: 10.1177/17588359241306026.

Epigenetic modulators provide a path to understanding disease and therapeutic opportunity.

Honer M, Ferman B, Gray Z, Bondarenko E, Whetstine J Genes Dev. 2024; 38(11-12):473-503.

PMID: 38914477 PMC: 11293403. DOI: 10.1101/gad.351444.123.

N-MYC regulates cell survival via eIF4G1 in inv(16) acute myeloid leukemia.

Peramangalam P, Surapally S, Veltri A, Zheng S, Burns R, Zhu N Sci Adv. 2024; 10(9):eadh8493.

PMID: 38416825 PMC: 10901375. DOI: 10.1126/sciadv.adh8493.

Non-canonical functions of EZH2 in cancer.

Zimmerman S, Lin P, Souroullas G Front Oncol. 2023; 13:1233953.

PMID: 37664059 PMC: 10473085. DOI: 10.3389/fonc.2023.1233953.

TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.

Tan S, Tan T, Yokomori R, Liao M, Huang X, Yeoh A Leukemia. 2023; 37(10):1969-1981.

PMID: 37591943 DOI: 10.1038/s41375-023-01993-y.

References

Mundo L, Ambrosio M, Raimondi F, Del Porro L, Guazzo R, Mancini V . Molecular switch from MYC to MYCN expression in MYC protein negative Burkitt lymphoma cases. Blood Cancer J. 2019; 9(12):91. PMC: 6868231. DOI: 10.1038/s41408-019-0252-2. View

Puissant A, Frumm S, Alexe G, Bassil C, Qi J, Chanthery Y . Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013; 3(3):308-23. PMC: 3672953. DOI: 10.1158/2159-8290.CD-12-0418. View

Kamminga L, Bystrykh L, de Boer A, Houwer S, Douma J, Weersing E . The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood. 2005; 107(5):2170-9. PMC: 1895717. DOI: 10.1182/blood-2005-09-3585. View

Ianevski A, He L, Aittokallio T, Tang J . SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics. 2017; 33(15):2413-2415. PMC: 5554616. DOI: 10.1093/bioinformatics/btx162. View

Thielemans N, Demeyer S, Mentens N, Gielen O, Provost S, Cools J . TAL1 cooperates with PI3K/AKT pathway activation in T-cell acute lymphoblastic leukemia. Haematologica. 2022; 107(10):2304-2317. PMC: 9521226. DOI: 10.3324/haematol.2021.279718. View

Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson M . The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017; 49(8):1211-1218. PMC: 5535770. DOI: 10.1038/ng.3909. View

Liu R, Shi P, Wang Z, Yuan C, Cui H . Molecular Mechanisms of Dysregulation in Cancers. Front Oncol. 2021; 10:625332. PMC: 7886978. DOI: 10.3389/fonc.2020.625332. View

Schmitz N, de Leval L . How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. Br J Haematol. 2016; 176(6):851-866. DOI: 10.1111/bjh.14473. View

Manso R, Bellas C, Martin-Acosta P, Mollejo M, Menarguez J, Rojo F . C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas. Haematologica. 2016; 101(8):e336-8. PMC: 4967584. DOI: 10.3324/haematol.2016.143768. View

10.

Durbin A, Zimmerman M, Dharia N, Abraham B, Iniguez A, Weichert-Leahey N . Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nat Genet. 2018; 50(9):1240-1246. PMC: 6386470. DOI: 10.1038/s41588-018-0191-z. View

11.

Zeid R, Lawlor M, Poon E, Reyes J, Fulciniti M, Lopez M . Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. Nat Genet. 2018; 50(4):515-523. PMC: 6310397. DOI: 10.1038/s41588-018-0044-9. View

12.

Verfaillie A, Imrichova H, Janky R, Aerts S . iRegulon and i-cisTarget: Reconstructing Regulatory Networks Using Motif and Track Enrichment. Curr Protoc Bioinformatics. 2015; 52:2.16.1-2.16.39. DOI: 10.1002/0471250953.bi0216s52. View

13.

Wei Y, Chen Y, Li L, Lang J, Yeh S, Shi B . CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol. 2010; 13(1):87-94. PMC: 3076036. DOI: 10.1038/ncb2139. View

14.

Jiao L, Shubbar M, Yang X, Zhang Q, Chen S, Wu Q . A partially disordered region connects gene repression and activation functions of EZH2. Proc Natl Acad Sci U S A. 2020; 117(29):16992-17002. PMC: 7382310. DOI: 10.1073/pnas.1914866117. View

15.

Rickman D, Schulte J, Eilers M . The Expanding World of N-MYC-Driven Tumors. Cancer Discov. 2018; 8(2):150-163. DOI: 10.1158/2159-8290.CD-17-0273. View

16.

Kawagoe H, Kandilci A, Kranenburg T, Grosveld G . Overexpression of N-Myc rapidly causes acute myeloid leukemia in mice. Cancer Res. 2007; 67(22):10677-85. DOI: 10.1158/0008-5472.CAN-07-1118. View

17.

Fiore D, Cappelli L, Broccoli A, Zinzani P, Chan W, Inghirami G . Peripheral T cell lymphomas: from the bench to the clinic. Nat Rev Cancer. 2020; 20(6):323-342. DOI: 10.1038/s41568-020-0247-0. View

18.

Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L . N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell. 2016; 30(4):563-577. PMC: 5540451. DOI: 10.1016/j.ccell.2016.09.005. View

19.

Althoff K, Beckers A, Bell E, Nortmeyer M, Thor T, Sprussel A . A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. Oncogene. 2014; 34(26):3357-68. PMC: 4487199. DOI: 10.1038/onc.2014.269. View

20.

Wong D, Liu H, Ridky T, Cassarino D, Segal E, Chang H . Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell. 2008; 2(4):333-44. PMC: 2628721. DOI: 10.1016/j.stem.2008.02.009. View